Safety and Pharmacokinetics of AT-007 in Healthy Subjects and in Adult Subjects With Classic Galactosemia
A Phase 1-2, Dose-Escalating, 4-Part Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of AT-007 in Healthy Adult Subjects and Adult Subjects With Classic Galactosemia
Sponsor: Applied Therapeutics, Inc.
A PHASE1/PHASE2 clinical study on Classic Galactosemia, this trial is completed. The trial is conducted by Applied Therapeutics, Inc. and has accumulated 8 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jul 2022 — Jun 2024 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
-
Apr 2022 — Jul 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 3 earlier versions
-
Jun 2021 — Apr 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2021 — Jun 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Nov 2019 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Jun 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Applied Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .